Ross Abrams to Neoadjuvant Therapy
This is a "connection" page, showing publications Ross Abrams has written about Neoadjuvant Therapy.
Connection Strength
1.417
-
Management of a patient with borderline resectable pancreatic cancer. Case report and review. Oncology (Williston Park). 2008 Nov 30; 22(13):1524-9.
Score: 0.333
-
Adjuvant therapy for pancreatic cancer: current status, future directions. Semin Oncol. 2006 Dec; 33(6 Suppl 11):S10-3.
Score: 0.290
-
Impact of radiation therapy facility volume on survival in patients with cancer. Cancer. 2021 11 01; 127(21):4081-4090.
Score: 0.201
-
Neoadjuvant Interdigitated Chemoradiotherapy Using Mesna, Doxorubicin, and Ifosfamide for Large, High-grade, Soft Tissue Sarcomas of the Extremity: Improved Efficacy and Reduced Toxicity. Am J Clin Oncol. 2019 01; 42(1):1-5.
Score: 0.167
-
Role of chemoradiotherapy in the adjuvant and neoadjuvant settings for resectable pancreatic cancer. Clin Oncol (R Coll Radiol). 2014 Sep; 26(9):551-9.
Score: 0.123
-
Radiotherapy for soft tissue sarcoma: 50 years of change and improvement. Am Soc Clin Oncol Educ Book. 2014; 244-51.
Score: 0.118
-
Combined modality treatment of resectable and borderline resectable pancreas cancer: expert consensus statement. Ann Surg Oncol. 2009 Jul; 16(7):1751-6.
Score: 0.086
-
Consensus Statement on Mandatory Measurements for Pancreatic Cancer Trials for Patients With Resectable or Borderline Resectable Disease (COMM-PACT-RB): A Systematic Review and Delphi Consensus Statement. JAMA Oncol. 2022 06 01; 8(6):929-937.
Score: 0.053
-
Is there a role for radiotherapy in the management of upper gastrointestinal malignancies? Surg Oncol Clin N Am. 2000 Jul; 9(3):525-38, ix.
Score: 0.046